The amyloidogenic pathological pathway model, suggests that there exists a dynamic equilibrium of Aβ among the three most relevant biological compartments - blood, cerebrospinal fluid (CSF), brain interstitial fluid (ISF). The medical community believes that CSF is propelled by a combination of hydrostatic pressure arising from its continuous production (at rate ~0.4ml/min), by arterial pulsations and by the respiratory cycle. The recent characterizations of the glymphatic and meningeal lymphatic systems in humans call for revaluation of the CSF production pathways and the anatomical routes for CSF–ISF flow and the physiological role that these pathways play in CNS health. We identified and scientifically proved the existence of a third neurofluid oscillator while studying the brain's glymphatic clearance system, an oscillator controlled by our spine motion. Using advanced fNIR brain imaging techniques developed by University of Oulu in Finland, we can now clearly measure oscillations of CSF caused by spine motion. Integrating SphygmoCor® ability to measure central blood pressures (cBP), vascular stiffness, vascular age, and heart stress into our research will provide invaluable insights into the cardio vascular component of CSF pulsations, enriching our understanding and therapeutic interventions. With precise digital vascular biomarkers, we aim to elucidate the intricate relationship between vascular system disfunction, neurofluid flow and Alzheimer's progression. The non-invasiveness of SphygmoCor® aligns perfectly with our mission to develop non-invasive Alzheimer's disease treatments. Furthermore, collaboration with CardieX offers a strategic partnership, fostering innovation and driving meaningful advancements in Alzheimer's treatment.